Skip to main content

Advertisement

Table 2 Clinical and microbiological characteristics of ESBL-producing hvKp isolates

From: Hypervirulent Klebsiella pneumoniae (hypermucoviscous and aerobactin positive) infection over 6 years in the elderly in China: antimicrobial resistance patterns, molecular epidemiology and risk factor

Clinical characteristic P14 P32 P34 P45 P51 P65 P92 P133 P145 P212 P221 P233 P237
Age   86 73 89 90 94 79 85 86 93 91 93 86
Gender M M M M M M M M M M M M M
Clinical department Cardiology ICU Urology CCU Respiratory ICU Endocrinology Respiratory Gastroenterology ICU Cardiology Respiratory CCU
Date of specimen (yr/mo/day) 2011/04/18 2010/10/10 2010/07/14 2008/10/24 2008/07/22 2010/10/14 2011/08/11 2011/07/11 2013/05/19 2014/01/21 2013/05/15 2013/09/11 2013/01/16
Main underlying diseases Cardiovascular diseases UIP Prostate Disease CHD Bronchiectasis Diabetes Diabetes UIP Diabetes UIP Heart failure Diabetes Diabetes
Tube CVC; ureter; stomach tube CVC; ureter; stomach tube; tracheal catheter CVC; ureter; stomach tube; tracheal catheter CVC; ureter; stomach tube Ureter; stomach tube CVC; ureter; stomach tube; Tracheal catheter CVC; ureter; stomach tube; tracheal catheter Non Non CVC; ureter; stomach tube; tracheal catheter CVC; ureter; stomach tube Stomach tube Stomach tube
Specimen type Sputum Sputum Urine Urine Sputum Sputum Sputum Sputum Sputum Sputum + blood Urine Sputum Sputum
Infection type Pneumonia Sepsis Sepsis Urinary infection Pneumonia Sepsis Sepsis Pneumonia Pneumonia Sepsis shock Urinary infection Pneumonia Pneumonia
WBC (109/L) 14.36 11.35 13.14 7.33 8.34 7.38 13.2 8.47 12.26 14.1 8.3 9.45 13.3
NEU (%) 82.9 87.6 81.3 69.2 67.5 66.3 83.1 70.5 78.3 64.4 69.3 81.3 76.3
TP (g/L) 67 63.7 75 61 58 60 61 69 68 61 64 62 67
ALB (g/L) 35.2 30.7 35.7 34.5 31.3 31.5 32.9 39 36.9 32.6 37.2 36.5 37.8
MDR Y Y Y Y Y Y Y N N Y Y Y N
Antibiotic resistance type Penicillins; cephalosporins; aminoglycosides; beta-lactamase inhibitor; quinolones Penicillins; cephalosporins; aminoglycosides Penicillins; cephalosporins; sulfonamides Penicillins; cephalosporins; aminoglycosides Penicillins; cephalosporins; aminoglycosides; beta-lactamase inhibitor; quinolones; Sulfonamides Penicillins; cephalosporins; aminoglycosides; beta-lactamase inhibitor; quinolones; Sulfonamides Penicillins; cephalosporins; quinolones Penicillins; cephalosporins; Penicillins; cephalosporins Penicillins; cephalosporins; aminoglycosides Penicillins; cephalosporins; aminoglycosides Penicillins; cephalosporins; sulfonamides Penicillins; cephalosporins
Empiric Therapy CIP + CAZ MEM + ISE CMZ IPM MXF CIP + CAZ IPM + ISE MXF MXF TZP + ISE MXF CIP + CAZ CIP + CAZ
Switched Therapy MEM MEM MXF TZP MEM CAZ + TZP IPM MXF MXF MEM + CIP MXF CIP + ISE CIP + ISE
SOFA score 6 7 10 3 5 7 8 3 5 11 5 7 6
Clinical outcome Survived Survived Survived Survived Survived Survived Survived Survived Survived Died Survived Survived Survived
String test length (mm) 100 30 50 100 40 20 200 45 20 60 8 8 50
Virulence-associated genes              
rmpA + + + + + + + +
rmpA2 + + + + + + +
magA + + + + + + + + + + + +
aerobactin + + + + + + + + + + + + +
cps genes              
K1 + +
K2
K5
K20
K54
K57 +
MLST genotyping 2899 2892 34 2888 1264 412 2898 2920 23 17 2836 101 23
Clone complex Singleton CC292 CC34 CC1 CC11 CC412 CC1 singleton CC23 CC17 CC292 CC101 CC23
  1. M male, ICU intensive care unit, CCU coronary care unit, UIP usual interstitial pneumonia, CHD coronary heart disease, CVC central venous catheter, CIP ciprofloxacin, MEM meropenem, IPM imipenem, TZP piperacillin tazobactam, ISE isepamicin, CMZ cefmetazole, MXF moxifloxacin, CAZ ceftazidime, Y yes, N no